modelVaginalRingWithProgestog
Extends from Pharmacolibrary.Drugs.ATC.G.G02BB01.
Information
| name: | VaginalRingWithProgestogenAndEstrogen | |
| ATC code: | G02BB01 | route: | vaginal |
| compartments: | 1 | |
| dosage: | 11.7 | mg |
| volume of distribution: | 2.0 | L |
| clearance: | 3.5 | L/h |
| other parameters in model implementation | ||
The vaginal ring containing progestogen and estrogen is a contraceptive device designed for intravaginal administration delivering a combination of an estrogen (usually ethinylestradiol) and a progestogen (such as etonogestrel). It provides effective reversible contraception and is approved for use by women of reproductive age.
Pharmacokinetics
Pharmacokinetic parameters estimated for a typical healthy adult female user, as reported for the etonogestrel/ethinylestradiol vaginal ring (e.g., NuvaRing).
References
Nelson, AL (2019). Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method. Expert review of clinical pharmacology 12(10) 953–963. DOI:10.1080/17512433.2019.1669448 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31526281
Thakur, K, et al., & Polak, S (2024). Development and verification of mechanistic vaginal absorption and metabolism model to predict systemic exposure after vaginal ring and gel application. British journal of clinical pharmacology 90(6) 1428–1449. DOI:10.1111/bcp.16029 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38450818
Shaaban, MM (1991). Contraception with progestogens and progesterone during lactation. The Journal of steroid biochemistry and molecular biology 40(4-6) 705–710. DOI:10.1016/0960-0760(91)90294-f PUBMED:https://pubmed.ncbi.nlm.nih.gov/1835650
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)